18F-AV-1451 positron emission tomography in neuropathological substrates of corticobasal syndrome.
暂无分享,去创建一个
Keith A. Johnson | Jessica A. Collins | B. Dickerson | J. Growdon | A. Schultz | M. Frosch | J. Locascio | M. Brickhouse | S. Gomperts | Alexandra Touroutoglou | A.E. Goodheart | Wesley R. Samore
[1] J. Klein,et al. Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome , 2019, JAMA neurology.
[2] Maria Luisa Gorno-Tempini,et al. 18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes , 2019, Alzheimer's Research & Therapy.
[3] J. Passchier,et al. Disease-related patterns of in vivo pathology in Corticobasal syndrome , 2018, European Journal of Nuclear Medicine and Molecular Imaging.
[4] S. Houle,et al. [18F]AV‐1451 binding and postmortem pathology of CBD , 2018, Movement disorders : official journal of the Movement Disorder Society.
[5] A. Drzezga,et al. Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia , 2018, European Journal of Nuclear Medicine and Molecular Imaging.
[6] J. Whitwell. Tau Imaging in Parkinsonism: What Have We Learned So Far? , 2018, Movement disorders clinical practice.
[7] Peter R. Martin,et al. [18F] AV-1451 uptake in corticobasal syndrome: the influence of beta-amyloid and clinical presentation , 2018, Journal of Neurology.
[8] M. Citron,et al. The tau positron‐emission tomography tracer AV‐1451 binds with similar affinities to tau fibrils and monoamine oxidases , 2018, Movement disorders : official journal of the Movement Disorder Society.
[9] Keith A. Johnson,et al. Flortaucipir tau PET imaging in semantic variant primary progressive aphasia , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.
[10] Keith A. Johnson,et al. 18F‐flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study , 2017, Annals of neurology.
[11] Hanna Cho,et al. 18F-AV-1451 binds to motor-related subcortical gray and white matter in corticobasal syndrome , 2017, Neurology.
[12] P. Svenningsson,et al. In vivo retention of 18F-AV-1451 in corticobasal syndrome , 2017, Neurology.
[13] Murray Grossman,et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria , 2017, Movement disorders : official journal of the Movement Disorder Society.
[14] Keith A. Johnson,et al. Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease , 2017, JAMA neurology.
[15] Virginia M. Y. Lee,et al. Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies , 2017, Brain : a journal of neurology.
[16] Luca Passamonti,et al. 18F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy , 2017, Brain : a journal of neurology.
[17] Daniel R. Schonhaut,et al. F-Flortaucipir Tau Positron Emission Tomography Distinguishes Established Progressive Supranuclear Palsy from Controls and Parkinson Disease: A Multicenter Study , 2017 .
[18] J. Trojanowski,et al. Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration , 2016, Acta Neuropathologica.
[19] Nick C Fox,et al. Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias , 2016, Alzheimer's & Dementia.
[20] C. Jack,et al. [18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration , 2016, Acta Neuropathologica.
[21] Clifford R. Jack,et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia , 2016, Acta Neuropathologica Communications.
[22] Ciprian Catana,et al. Different partial volume correction methods lead to different conclusions: An 18F-FDG-PET study of aging , 2016, NeuroImage.
[23] A. Berardelli,et al. Gray and white matter structural changes in corticobasal syndrome , 2016, Neurobiology of Aging.
[24] Jorge Sepulcre,et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease , 2016, Annals of neurology.
[25] Keith A. Johnson,et al. Validating novel tau positron emission tomography tracer [F‐18]‐AV‐1451 (T807) on postmortem brain tissue , 2015, Annals of neurology.
[26] Christopher C Rowe,et al. Tau imaging: early progress and future directions , 2015, The Lancet Neurology.
[27] R. Takahashi,et al. Ultrastructural differences in pretangles between Alzheimer disease and corticobasal degeneration revealed by comparative light and electron microscopy , 2014, Acta neuropathologica communications.
[28] J. Trojanowski,et al. Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases , 2013, The Journal of comparative neurology.
[29] Keith A. Johnson,et al. A concise radiosynthesis of the tau radiopharmaceutical, [(18) F]T807. , 2013, Journal of labelled compounds & radiopharmaceuticals.
[30] H. Kolb,et al. [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease , 2013, Alzheimer's & Dementia.
[31] Mark Hallett,et al. Criteria for the diagnosis of corticobasal degeneration , 2013, Neurology.
[32] Min-Ying Su,et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. , 2013, Journal of Alzheimer's disease : JAD.
[33] J. Schneider,et al. National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.
[34] J. Trojanowski,et al. Clinicopathological correlations in corticobasal degeneration , 2011, Annals of neurology.
[35] A. Lees,et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. , 2010, Brain : a journal of neurology.
[36] Nathaniel Mercaldo,et al. The Alzheimer's Disease Centers' Uniform Data Set (UDS): The Neuropsychologic Test Battery , 2009, Alzheimer disease and associated disorders.
[37] Akram Bakkour,et al. The cortical signature of prodromal AD , 2009, Neurology.
[38] J. Morris,et al. The Cortical Signature of Alzheimer's Disease: Regionally Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD Dementia and is Detectable in Asymptomatic Amyloid-Positive Individuals , 2008, Cerebral cortex.
[39] J. Jankovic,et al. Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.
[40] J. Vonsattel,et al. Twenty-first century brain banking. Processing brains for research: the Columbia University methods , 2007, Acta Neuropathologica.
[41] J. Schneider,et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration , 2007, Acta Neuropathologica.
[42] J. Jankovic,et al. Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan , 2007, Movement disorders : official journal of the Movement Disorder Society.
[43] J. Cummings,et al. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.
[44] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[45] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.
[46] Nikos Makris,et al. Automatically parcellating the human cerebral cortex. , 2004, Cerebral cortex.
[47] W. Klunk,et al. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. , 2003, Journal of medicinal chemistry.
[48] P. Lantos,et al. Office of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration , 2002, Journal of neuropathology and experimental neurology.
[49] A M Dale,et al. Measuring the thickness of the human cerebral cortex from magnetic resonance images. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[50] R. Petersen,et al. Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia , 1999, Neurology.
[51] J. Morris,et al. Clinical Dementia Rating: A Reliable and Valid Diagnostic and Staging Measure for Dementia of the Alzheimer Type , 1997, International Psychogeriatrics.
[52] N. Volkow,et al. Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[53] S. M. Sumi,et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.
[54] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[55] E. Richardson,et al. Corticodentatonigral degeneration with neuronal achromasia: a progressive disorder of late adult life. , 1967, Transactions of the American Neurological Association.